Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy

Minyong Kang, Jae Young Park, Chang Wook Jeong, Eu Chang Hwang, Cheryn Song, Sung Hoo Hong, Cheol Kwak, Jinsoo Chung, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Se Hoon Park, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Seong Il Seo

Research output: Contribution to journalArticle

Abstract

Purpose: In this study we evaluated conditional survival probabilities in patients with metastatic renal cell carcinoma who underwent first line tyrosine kinase inhibitor therapy. We also identified predictors of conditional survival with time. Materials and Methods: We retrospectively reviewed clinical data on 1,659 individuals with metastatic renal cell carcinoma in the Korean Renal Cancer Study Group database, of whom the records of 1,131 were finally analyzed. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities using the formula, conditional survival (α│β) = S(α + β)/S(β), indicating the likelihood of additional α years survivorship in person who has already survived for β years after initial therapy. S(χ) represents the actual survival rate. Multivariate Cox regression model was used to identify predictors of conditional survival with time. Results: Six, 12, 18, 24 and 36-month conditional overall survival gradually increased in patients at all additional survival times after initial treatment compared to patient baseline survival estimations. While the actual overall survival rate decreased with time, the 36-month conditional overall survival rate was calculated as 7.3% higher in patients who had already survived 36 months compared to baseline estimations at the time of initial tyrosine kinase inhibitor treatment. Furthermore, predictors of conditional overall survival changed with time. Only previous metastasectomy remained a key prognosticator of conditional overall survival until 36 months of survival following initial tyrosine kinase inhibitor treatment. Conclusions: Conditional survival improved with time after initial tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma. Our study offers valuable information for practical survival estimations and relevant prognosticators in patients with metastatic renal cell carcinoma who receive first line tyrosine kinase inhibitor.

Original languageEnglish
Pages (from-to)989-995
Number of pages7
JournalJournal of Urology
Volume200
Issue number5
DOIs
StatePublished - 1 Nov 2018

Fingerprint

Renal Cell Carcinoma
Survival Rate
Survival
Protein-Tyrosine Kinases
Therapeutics
Metastasectomy
Kidney Neoplasms
Kaplan-Meier Estimate
Survival Analysis
Proportional Hazards Models
Databases

Keywords

  • carcinoma
  • kidney
  • mortality
  • neoplasm metastasis
  • protein-tyrosine kinases
  • renal cell

Cite this

Kang, Minyong ; Park, Jae Young ; Jeong, Chang Wook ; Hwang, Eu Chang ; Song, Cheryn ; Hong, Sung Hoo ; Kwak, Cheol ; Chung, Jinsoo ; Sung, Hyun Hwan ; Jeon, Hwang Gyun ; Jeong, Byong Chang ; Park, Se Hoon ; Jeon, Seong Soo ; Lee, Hyun Moo ; Choi, Han Yong ; Seo, Seong Il. / Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. In: Journal of Urology. 2018 ; Vol. 200, No. 5. pp. 989-995.
@article{069f6c80de4848149de294cc68c63296,
title = "Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy",
abstract = "Purpose: In this study we evaluated conditional survival probabilities in patients with metastatic renal cell carcinoma who underwent first line tyrosine kinase inhibitor therapy. We also identified predictors of conditional survival with time. Materials and Methods: We retrospectively reviewed clinical data on 1,659 individuals with metastatic renal cell carcinoma in the Korean Renal Cancer Study Group database, of whom the records of 1,131 were finally analyzed. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities using the formula, conditional survival (α│β) = S(α + β)/S(β), indicating the likelihood of additional α years survivorship in person who has already survived for β years after initial therapy. S(χ) represents the actual survival rate. Multivariate Cox regression model was used to identify predictors of conditional survival with time. Results: Six, 12, 18, 24 and 36-month conditional overall survival gradually increased in patients at all additional survival times after initial treatment compared to patient baseline survival estimations. While the actual overall survival rate decreased with time, the 36-month conditional overall survival rate was calculated as 7.3{\%} higher in patients who had already survived 36 months compared to baseline estimations at the time of initial tyrosine kinase inhibitor treatment. Furthermore, predictors of conditional overall survival changed with time. Only previous metastasectomy remained a key prognosticator of conditional overall survival until 36 months of survival following initial tyrosine kinase inhibitor treatment. Conclusions: Conditional survival improved with time after initial tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma. Our study offers valuable information for practical survival estimations and relevant prognosticators in patients with metastatic renal cell carcinoma who receive first line tyrosine kinase inhibitor.",
keywords = "carcinoma, kidney, mortality, neoplasm metastasis, protein-tyrosine kinases, renal cell",
author = "Minyong Kang and Park, {Jae Young} and Jeong, {Chang Wook} and Hwang, {Eu Chang} and Cheryn Song and Hong, {Sung Hoo} and Cheol Kwak and Jinsoo Chung and Sung, {Hyun Hwan} and Jeon, {Hwang Gyun} and Jeong, {Byong Chang} and Park, {Se Hoon} and Jeon, {Seong Soo} and Lee, {Hyun Moo} and Choi, {Han Yong} and Seo, {Seong Il}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.juro.2018.06.030",
language = "English",
volume = "200",
pages = "989--995",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

Kang, M, Park, JY, Jeong, CW, Hwang, EC, Song, C, Hong, SH, Kwak, C, Chung, J, Sung, HH, Jeon, HG, Jeong, BC, Park, SH, Jeon, SS, Lee, HM, Choi, HY & Seo, SI 2018, 'Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy', Journal of Urology, vol. 200, no. 5, pp. 989-995. https://doi.org/10.1016/j.juro.2018.06.030

Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. / Kang, Minyong; Park, Jae Young; Jeong, Chang Wook; Hwang, Eu Chang; Song, Cheryn; Hong, Sung Hoo; Kwak, Cheol; Chung, Jinsoo; Sung, Hyun Hwan; Jeon, Hwang Gyun; Jeong, Byong Chang; Park, Se Hoon; Jeon, Seong Soo; Lee, Hyun Moo; Choi, Han Yong; Seo, Seong Il.

In: Journal of Urology, Vol. 200, No. 5, 01.11.2018, p. 989-995.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy

AU - Kang, Minyong

AU - Park, Jae Young

AU - Jeong, Chang Wook

AU - Hwang, Eu Chang

AU - Song, Cheryn

AU - Hong, Sung Hoo

AU - Kwak, Cheol

AU - Chung, Jinsoo

AU - Sung, Hyun Hwan

AU - Jeon, Hwang Gyun

AU - Jeong, Byong Chang

AU - Park, Se Hoon

AU - Jeon, Seong Soo

AU - Lee, Hyun Moo

AU - Choi, Han Yong

AU - Seo, Seong Il

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: In this study we evaluated conditional survival probabilities in patients with metastatic renal cell carcinoma who underwent first line tyrosine kinase inhibitor therapy. We also identified predictors of conditional survival with time. Materials and Methods: We retrospectively reviewed clinical data on 1,659 individuals with metastatic renal cell carcinoma in the Korean Renal Cancer Study Group database, of whom the records of 1,131 were finally analyzed. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities using the formula, conditional survival (α│β) = S(α + β)/S(β), indicating the likelihood of additional α years survivorship in person who has already survived for β years after initial therapy. S(χ) represents the actual survival rate. Multivariate Cox regression model was used to identify predictors of conditional survival with time. Results: Six, 12, 18, 24 and 36-month conditional overall survival gradually increased in patients at all additional survival times after initial treatment compared to patient baseline survival estimations. While the actual overall survival rate decreased with time, the 36-month conditional overall survival rate was calculated as 7.3% higher in patients who had already survived 36 months compared to baseline estimations at the time of initial tyrosine kinase inhibitor treatment. Furthermore, predictors of conditional overall survival changed with time. Only previous metastasectomy remained a key prognosticator of conditional overall survival until 36 months of survival following initial tyrosine kinase inhibitor treatment. Conclusions: Conditional survival improved with time after initial tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma. Our study offers valuable information for practical survival estimations and relevant prognosticators in patients with metastatic renal cell carcinoma who receive first line tyrosine kinase inhibitor.

AB - Purpose: In this study we evaluated conditional survival probabilities in patients with metastatic renal cell carcinoma who underwent first line tyrosine kinase inhibitor therapy. We also identified predictors of conditional survival with time. Materials and Methods: We retrospectively reviewed clinical data on 1,659 individuals with metastatic renal cell carcinoma in the Korean Renal Cancer Study Group database, of whom the records of 1,131 were finally analyzed. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities using the formula, conditional survival (α│β) = S(α + β)/S(β), indicating the likelihood of additional α years survivorship in person who has already survived for β years after initial therapy. S(χ) represents the actual survival rate. Multivariate Cox regression model was used to identify predictors of conditional survival with time. Results: Six, 12, 18, 24 and 36-month conditional overall survival gradually increased in patients at all additional survival times after initial treatment compared to patient baseline survival estimations. While the actual overall survival rate decreased with time, the 36-month conditional overall survival rate was calculated as 7.3% higher in patients who had already survived 36 months compared to baseline estimations at the time of initial tyrosine kinase inhibitor treatment. Furthermore, predictors of conditional overall survival changed with time. Only previous metastasectomy remained a key prognosticator of conditional overall survival until 36 months of survival following initial tyrosine kinase inhibitor treatment. Conclusions: Conditional survival improved with time after initial tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma. Our study offers valuable information for practical survival estimations and relevant prognosticators in patients with metastatic renal cell carcinoma who receive first line tyrosine kinase inhibitor.

KW - carcinoma

KW - kidney

KW - mortality

KW - neoplasm metastasis

KW - protein-tyrosine kinases

KW - renal cell

UR - http://www.scopus.com/inward/record.url?scp=85053637988&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2018.06.030

DO - 10.1016/j.juro.2018.06.030

M3 - Article

C2 - 29940249

AN - SCOPUS:85053637988

VL - 200

SP - 989

EP - 995

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -